V590

V590 Uses, Dosage, Side Effects, Food Interaction and all others data.

The V590 vaccine was developed on Merck’s recombinant vesicular stomatitis virus (rVSV) platform that was previously used to develop its Ebola Zaire virus vaccine, ERVEBO®. By teaming up with IAVI, Merk developed a vaccine that does not require freezing, and only requires one dose. Other features of this vaccine include potential activity with oral administration via a swish-and-swallow protocol. Merck is currently underway to begin Phase I trials for the vaccine through intramuscular administration (NCT04569786).

Trade Name	V590
Generic	V590
Type
Groups	Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Innovators Monograph

You find simplified version here V590